This year’s Myeloma UK London Paris Ride saw 137 people including myeloma patients and their friends and family, doctors and nurses, and employees from the pharmaceutical industry join together to cycle 500km in four days.
The final day saw participants enter Paris as part of a huge peloton under police escort, where they cycled past the Arc de Triomphe before crossing the finish line near the Eiffel Tower.
You can catch up on the ride by watching our daily videos from the event on our dedicated ride website. Watch our parody video below:
Myeloma UK Director of Fundraising Barbara Osborne said, “Congratulations to all of our participants! The ride was a truly amazing show of solidarity with the patients and their families who are living with myeloma. We receive no Government funding, and so it’s thanks to our amazing fundraisers and events like this that we can continue to support research into myeloma, and of course myeloma patients across the UK.”
Ride Ambassador, record-breaking round the world cyclist and ultra-endurance adventurer, Mark Beaumont said, “Cycling from London to Paris is not easy. It takes determination, focus and commitment. A massive well done to all the riders!” Mark kicked off the ride and cycled with participants on Day One to see them off at the Channel Tunnel.
Among this year’s participants was actor and myeloma patient Michael Thomas. Michael’s sister Chris Grady took part in the London to Paris Ride last year. He said, “I met my sister in Paris at the end of last year’s London to Paris. Her experience was overwhelmingly positive, and this year I knew I had to take part. I’m thrilled to have been able to support the work of Myeloma UK.”
You can catch up with all the action by visiting our dedicated ride website.
You can also made a donation to show your support for our riders on our JustGiving page:
The 2017 London Paris Ride was sponsored by A.G. Barr, Hype Branding, HIGH5, Barr Printers, Tunnock’s and Gobstoppers and was supported by teams from our pharmaceutical partners Amgen, Celgene and Takeda.